-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On January 25, Pfizer and BioNTech jointly announced the initiation of a clinical trial to evaluate the protective efficacy of Omicron's proprietary vaccine in healthy adults aged 18-55
This study is divided into 3 cohorts.
Cohort #1 (n=615): Received two doses of the current Pfizer-BioNTech COVID-19 vaccine 90-180 days prior to enrollment; in this study, will receive one or two doses of the Omicron-based vaccine
Cohort #2 (n=600): Received three doses of current Pfizer-BioNTech COVID-19 vaccine 90-180 days prior to enrollment; in this study, will receive one dose of current Pfizer-BioNTech COVID-19 vaccine or Omicron-based vaccines
Cohort #3 (n=205): Unvaccinated subjects who received three doses of Omicron-based vaccine
Previous vaccines continue to provide strong protection against Omicron-induced new coronary pneumonia.
However, in the press release, Pfizer also stated that the current new crown vaccine continues to provide protection for vaccinated people, especially those who have received booster shots, significantly reducing severe illness and hospitalization rates
Source: https://investors.
